Expansion of Compassionate Access Programme
The Compassionate Access Programme has expaned to 37 patients per month thanks to the generosity of others.
Australian expansion
Rua Bioscience expands its product range in Australia.
Rua Bioscience partners with Cannprisma for trials in Portugal
Psilocybin mushroom programme
Rua Bioscience Impact Programme gains further support from Trust Tairawhiti
Rua Releases Half Year Results (HY24)
Expanding reach to Canada
2023 at a glance
Rua Bioscience Celebrates 2023 Scholars Driving Positive Change in Te Tairāwhiti
Rua Bioscience Celebrates 2023 Scholars Driving Positive Change in Te Tairāwhiti
Changes to Supply Agreement with Cann Group
Market Update - Global Market Expansion with Unique New Zealand Genetics
Global Market Expansion with Unique New Zealand Genetics
First Licence for Psilocybe (Magic Mushroom) Cultivation in NZ
Indigenous psilocybin clinial trials team, Rangiwaho Marae, July 2023. Copyright: Rangiwaho Marae
Shareholders and Community Engagement Day
Shareholders and Community Engagement Day 2023
Rua Bioscience launches first product in Australia
Rua Bioscience is positioned for growth, establishing collaborative networks and seizing opportunity in the booming Australian cannabis market.
2023 - Shareholder’s Annual Results
2023 Annual Shareholders’ Meeting and Director Nominations
Germany Brand Launch Event - Rua and Nimbus.
On a beautiful rooftop venue in Berlin, Germany, Rua Bioscience and Nimbus Health joined forces to co-host an unforgettable brand launch event. The evening was focused on sharing the Rua story with doctors, pharmacists and patients.
First Revenue from Germany
Shareholders Newsletter
Rua Bioscience Launches in Germany
Rua Bioscience has successfully launched its first medicine in Germany. In doing so, the company has become one of the first medicinal cannabis company in New Zealand to introduce a branded product in Europe’s largest medicinal cannabis market.